AKUMS

Akums Drugs and Pharmaceuticals Ltd. announced its participation in a physical Investor/Analysts Conference Call (group meet) on June 1st, 2026, at 09:00 AM (IST) at Grand Hyatt, Mumbai. The company noted that the intimation for the meeting was delayed as the decision process took more time than anticipated. No unpublished price sensitive information will be shared during the meet.

Akums Drugs and Pharmaceuticals Limited's wholly-owned subsidiaries (Maxcure Nutravedics, Pure and Cure Healthcare, Malik Lifesciences, and Nicholas Healthcare) received assessment orders from the Income Tax Department under Section 158BC of the Income Tax Act, 1961, for the block period from April 1, 2018, to March 12, 2025. The total demand across these subsidiaries is approximately ₹22.25 crores, primarily due to the disallowance of various expenditures. Akums, based on internal assessment, does not expect a material financial impact and intends to pursue an appeal against these orders.

Management reported a strong Q4 FY26, navigating a challenging H1 FY26. They guided for double-digit volume growth in CDMO for H1 FY27, with margins potentially improving to 15-16% driven by new capacity and European/Zambia contracts. Domestic branded formulations are expected to achieve double-digit top-line growth in line with IPM rates, and international branded formulations are targeted for double-digit growth. API losses are expected to reduce sharply in FY27, with an aspiration for monthly EBITDA positivity. The company announced an annual EUR35 million European CDMO contract from FY28 and $25 million in supplies to Zambia for FY27 and FY28, with a local facility investment of $45 million (51% equity) starting revenue in FY29/FY30. FY27 capex is targeted at INR300 crores. The Board recommended a final dividend of INR1 and a special dividend of INR2 per equity share.

Akums Drugs and Pharmaceuticals Limited and its subsidiary Akumentis Healthcare Ltd. received assessment orders from the Income Tax Department on May 20, 2026. Akums faces a demand of ₹60.09 Cr, and Akumentis Healthcare Ltd. faces ₹73.66 Cr, totaling ₹133.75 Cr, for the block period 01.04.2018 to 12.03.2025, due to disallowance of various expenditures. The company intends to appeal the orders, stating the demand is not sustainable in law and does not expect a material financial impact.

Akums Drugs & Pharmaceuticals Limited announced the audio recording of its investors/analysts conference call held on May 18, 2026, at 12:00 PM (IST). The call discussed the un-audited financial results of Q4 FY 2026 and audited financial results for FY 2026. The recording is available via a provided link, and the transcript will be shared with exchanges and uploaded to the company's website in due course.

Akums Drugs and Pharmaceuticals Limited announced that all manufacturing operations at its Haridwar sites have successfully resumed 100% capacity from May 18, 2026, following a four-day partial disruption. This disruption resulted in delayed supply of approximately INR 20 Cr, which the company expects to make up. There was no damage to property, and no insurance claim was filed.

Akums Drugs and Pharmaceuticals Ltd. provided an update on the disruption in operations at its Haridwar manufacturing sites, caused by industry-wide labor unrest concerning minimum wage review. The company confirmed that over 70% of operations at the affected sites have successfully resumed as of May 16, 2026, and productivity levels are expected to progressively improve. The loss of production caused by this unrest is covered under an industrial insurance policy, and there was no damage to company property.

Akums Drugs & Pharmaceuticals reported Q4 FY26 Revenue of ₹1,158Cr vs ₹1,056Cr (▲9.7% YoY), Adj EBITDA ₹152Cr vs ₹94Cr (▲61.6% YoY), and Adj PAT ₹83Cr vs ₹35Cr (▲135% YoY). Adj EBITDA Margin expanded to 13.1% vs 8.9% (▲420bps). The Board recommended a final dividend of INR 1 per equity share and a special dividend of INR 2 per equity share. The company achieved significant progress in global expansion and regulatory milestones.

Akums Drugs and Pharmaceuticals Limited reported a temporary disruption of operations at some manufacturing sites in Haridwar, effective May 14, 2026, due to labour unrest. The company is actively working with local authorities and workers to resolve the issue and normalize operations. Further updates on the impact will be provided.

The Board approved Q4 FY26 and FY26 financial results and recommended a total dividend of Rs. 3.00/- (Rs. 1.00/- final + Rs. 2.00/- special) per equity share for FY26. The Board also handled auditor re-appointments and senior management changes. A key concern is the ongoing Income Tax search and seizure operation from FY25, resulting in a show cause notice whose financial impact is currently unascertainable.

The Board approved financial results for Q4 and FY26 and recommended a final dividend of Rs. 1.00 and a special dividend of Rs. 2.00 per equity share for FY26. Mr. Arvind Srivastava (President - HR) ceased, and Mr. V Jagannathan was appointed as President - HR. The auditor's report highlighted an Income Tax search and seizure in January 2025 and a subsequent show cause notice, with the impact currently unascertainable.

The Board approved Q4 and FY26 financial results and recommended a final dividend of ₹1.00/- and a special dividend of ₹2.00/- per equity share for FY26, with July 03, 2026, as the record date. Mr. Arvind Srivastava ceased as President - HR, replaced by Mr. V Jagannathan. An Income Tax search and seizure operation from Jan 2025, with a subsequent show cause notice (SCN) received post-Mar 2026, has an unascertaninable impact on financial results, as highlighted by auditors. The 22nd AGM is scheduled for July 10, 2026.

Akums Drugs & Pharmaceuticals Limited announced the outcome of its Board Meeting held on May 14, 2026. The Board approved the financial results for Q4 and FY26 and recommended a final dividend of Rs. 1.00/- and a special dividend of Rs. 2.00/- per equity share for FY26. Mr. Arvind Srivastava ceased as President - HR, and Mr. V Jagannathan was appointed as his successor. The auditor's report highlighted an ongoing Income Tax search and seizure operation from FY25 and a subsequent show cause notice, with the impact currently unascertainable.

Standalone Revenue ₹338.37Cr vs ₹328.75Cr (▲2.93% YoY), EBITDA ₹36.81Cr vs ₹49.77Cr (▼26.05% YoY), PAT ₹15.20Cr vs ₹27.59Cr (▼44.91% YoY). EBITDA Margin 10.88% vs 15.14% (▼426bps). The Board recommended a final dividend of Rs. 1.00/- and a special dividend of Rs. 2.00/- per share for FY26. Auditors highlighted an ongoing Income Tax search and seizure operation from FY25, with its impact on current financials still unascertainable.

Akums Drugs & Pharmaceuticals' Board approved Q4 and FY26 financial results, recommending a final dividend of Rs. 1.00/- and a special dividend of Rs. 2.00/- per equity share. July 3, 2026, is the record date. The auditors highlighted an ongoing Income Tax search and seizure operation from FY25, whose impact on FY26 results is not yet ascertainable. Changes in Senior Management were also approved.

Standalone Revenue ₹3,383.72 million vs ₹3,287.53 million (▲2.93% YoY), EBITDA ₹90.76 million vs ₹177.24 million (▼48.79% YoY), PAT ₹151.97 million vs ₹275.89 million (▼44.92% YoY). EBITDA Margin 2.68% vs 5.39% (▼271bps).

Akums Drugs and Pharmaceuticals Limited announced an Analysts Conference Call (group meet) for Q4 and audited FY2026 results on May 18, 2026, at 12:00 PM (IST). The virtual call, coordinated by ICICI Securities, will feature key management including Mr. Sanjeev Jain (MD), Mr. Sandeep Jain (MD), Mr. Sumeet Sood (CFO), and Mr. Sahil Maheshwari (Head Strategy) to discuss the financial performance.